Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (TSE:NGEN)
:NGEN
NGEN Stock Chart & Stats
C$8.08
C$0.01(0.33%)
At close: 4:00 PM EST
C$8.08
C$0.01(0.33%)
Day’s Range― - ―
52-Week RangeC$2.57 - C$8.49
Previous CloseN/A
Volume11.98K
Average Volume (3M)93.83K
Market Cap
C$643.12M
Enterprise ValueC$231.86M
Total Cash (Recent Filing)C$15.73M
Total Debt (Recent Filing)C$57.71K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Apr 02, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding79,593,760
10 Day Avg. Volume180,731
30 Day Avg. Volume93,835
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)82.04
Price to Sales (P/S)0.00
P/FCF Ratio-12.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$10.72Price Target Upside32.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NervGen Pharma News
NGEN FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was C$2.57 and its highest was C$8.49 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is C$643.12M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Apr 02, 2026 which is in 82 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Nov 24, 2025. The company reported -C$0.06 earnings per share for the quarter, beating the consensus estimate of -C$0.085 by C$0.025.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.05.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 79,593,760 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -C$0.06 in its last earnings report, beating expectations of -C$0.085. Following the earnings report the stock price went up 11.25%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in TSE:NGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$10.72 (32.63% Upside)
C$10.72 (32.63% Upside)
Insider Transactions
Bought Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.45%
12-Months-Change
Fundamentals
Return on Equity
-790.82%
Trailing 12-Months
Asset Growth
-39.15%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
NGEN Stock 12 Month Forecast
Average Price Target
C$10.72
▲(32.63% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Fennec Pharmaceuticals
―
Bright Minds Biosciences
―
Eupraxia Pharmaceuticals
―
Options Prices
Currently, No data available
---